Elisha Wachman, MD
banner
elishawachman.bsky.social
Elisha Wachman, MD
@elishawachman.bsky.social
Neonatologist at Boston Medical Center | Vice Chair for Research BMC Peds | Neonatal Opioid Withdrawal Syndrome researcher
Association of Prenatal Fentanyl Exposure With Neonatal Opioid Withdrawal Syndrome Severity
OBJECTIVE. Opioid use disorder (OUD) in pregnancy has increased substantially, with illicit fentanyl now the most common illicit opioid. Limited data exist on the impact of antenatal fentanyl exposure on neonatal opioid withdrawal syndrome (NOWS). We aimed to evaluate whether antenatal fentanyl exposure is associated with increased NOWS severity.PATIENTS AND METHODS. We conducted a retrospective cohort study of mother–infant dyads with OUD between 2017 and 2024. Fentanyl exposure was determined by urine toxicology during the pregnancy and on admission. Infants were monitored using the Eat, Sleep, Console tool and a standardized NOWS protocol. NOWS hospitalization outcomes were compared between the fentanyl-exposed and nonexposed groups with adjustment for breastfeeding, year of birth, and relevant co-exposures.RESULTS. Among 504 dyads, 131 (26.0%) had fentanyl exposure. Maternal demographics were similar between groups, but fentanyl was associated with higher rates of polysubstance use. Fentanyl-exposed infants were more likely to receive pharmacologic NOWS treatment (61.1% vs 40.8%, P < .01), scheduled methadone dosing, secondary pharmacologic agents (15.4% vs 7.4%, P = .03), and feeding tubes (40.0% vs 24.5%, P < .001). Hospital length of stay (22.1 vs 13.3 days, P < .01) and opioid treatment duration (14.2 vs 9.4 days, P < .01) were longer in the fentanyl-exposed cohort. In adjusted regression models, fentanyl exposure remained independently associated with prolonged hospitalization (mean difference 5.1 days [95% CI 1.7–8.5]) and increased odds of pharmacologic treatment (adjusted odds ratio 2.1 [95% CI 1.2–3.8]).CONCLUSION. Antenatal fentanyl exposure is strongly associated with intensive pharmacologic management and extended hospitalization. These findings are suggestive of more severe NOWS.
publications.aap.org
April 22, 2026 at 6:48 PM
Association of Prenatal Fentanyl Exposure With Neonatal Opioid Withdrawal Syndrome Severity
OBJECTIVE. Opioid use disorder (OUD) in pregnancy has increased substantially, with illicit fentanyl now the most common illicit opioid. Limited data exist on the impact of antenatal fentanyl exposure on neonatal opioid withdrawal syndrome (NOWS). We aimed to evaluate whether antenatal fentanyl exposure is associated with increased NOWS severity.PATIENTS AND METHODS. We conducted a retrospective cohort study of mother–infant dyads with OUD between 2017 and 2024. Fentanyl exposure was determined by urine toxicology during the pregnancy and on admission. Infants were monitored using the Eat, Sleep, Console tool and a standardized NOWS protocol. NOWS hospitalization outcomes were compared between the fentanyl-exposed and nonexposed groups with adjustment for breastfeeding, year of birth, and relevant co-exposures.RESULTS. Among 504 dyads, 131 (26.0%) had fentanyl exposure. Maternal demographics were similar between groups, but fentanyl was associated with higher rates of polysubstance use. Fentanyl-exposed infants were more likely to receive pharmacologic NOWS treatment (61.1% vs 40.8%, P < .01), scheduled methadone dosing, secondary pharmacologic agents (15.4% vs 7.4%, P = .03), and feeding tubes (40.0% vs 24.5%, P < .001). Hospital length of stay (22.1 vs 13.3 days, P < .01) and opioid treatment duration (14.2 vs 9.4 days, P < .01) were longer in the fentanyl-exposed cohort. In adjusted regression models, fentanyl exposure remained independently associated with prolonged hospitalization (mean difference 5.1 days [95% CI 1.7–8.5]) and increased odds of pharmacologic treatment (adjusted odds ratio 2.1 [95% CI 1.2–3.8]).CONCLUSION. Antenatal fentanyl exposure is strongly associated with intensive pharmacologic management and extended hospitalization. These findings are suggestive of more severe NOWS.
publications.aap.org
April 22, 2026 at 6:48 PM
Our new article on placental transcriptomics after prenatal opioid exposure: authors.elsevier.com/c/1keEoWcm3P...
February 20, 2025 at 1:22 PM
Reposted by Elisha Wachman, MD
The entire website for the NIH Office of Research on Women's Health (ORWH) is very nearly stripped bare. This is so, so devastating. orwh.od.nih.gov/research/fun...
orwh.od.nih.gov
January 31, 2025 at 6:25 PM
Our new review on the genetics of Neonatal Opioid Withdrawal Syndrome: www.sciencedirect.com/science/arti...
The role of genetics in neonatal abstinence syndrome
Neonatal Abstinence Syndrome (NAS) after in-utero exposure to opioids remains a significant public health concern. NAS is a highly variable condition …
www.sciencedirect.com
November 29, 2024 at 7:29 AM
I have entered the "refresh ERA commons every hour" in search of a score phase of the grant cycle 🙏😬
November 20, 2024 at 1:50 PM